jurnalul român de psihofarmacologie romanian journal of ...

25. Vaughan GF, Leiberman DM, Cook LC. Chlorpromazine in psychiatry. Lancet 1955;
6874:1083-7.
26. Bennet JS, Kooi KA. Five phenotiazine derivatives. Arch Gen Psychiatry 1961; 4:413-8.
27. Casey JF, Lasky JJ, Klett CJ, Hollister LE. Treatment of schizophrenic reactions with
phenotiazine derivatives. Am J Psychiatry 1960: 117:97-105.
28. Fox W, Gobble IF, Clos M. A clinical comparison of trifluperidol, haloperidol and
chlorpromazine. Curr Ther Res 1964; 6:409-15.
29. Goldstein BJ, Clyde DJ. Haloperidol in controlling the symptoms of acute psychoses, part II: a
double-blind evaluation of haloperidol and trifluoperazine. Curr Ther Res 1966; 8:236-241.
30. Hanlon TE, Michaux MH, Ota KY, Shaffer JW, Kurland AA. The comparative
effectiveness of eight phenothiazines. Psychopharmacologia 1965; 7:89-106.
31. Leitch A, Seager CP. A clinical trial of four tranquilizing drugs. J Ment Sci 1960;
106:1093-1098.
32. NIMH Psychopharmacology Research Branch Collaborative Study Group. Differences in
clinical effects of three phenothiazines in acute schizophrenia. Dis Nerv Syst 1967; 28:369-383.
33. Pratt JP, Bishop MP, Gallant DM. Comparison of haloperidol, trifluperidol and
chlorpromazine in acute schizophrenic patients. Curr Ther Res 1964; 6:562-594.
34. Casey DE. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia.
Schizophr Res 1991; 4:109-120.
35. Claghorn J, Honigfeld G, Abuzzahab Sr FS, Wang R, Steinbook R, Tuason V, Klerman G.
The risks and benefits of clozapine vs. chlorpromazine. J Clin Psychopharmacol 1987;
7:377-384.
36. Kane J, Honigfeld G, Singer J, Meltzer H, the Clozaril Collaborative Study Group.
Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988; 45:789-796
37. Leysen JE. Receptor profile of antipsychotics. In: Atypical Antipsychotics (eds: Ellenbrock
BA, Cools AR), Bikhauser Verlag, Basel 2000:57-81.
38. Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: a critical
analysis. Psychopharmacology 1996; 124:2-34.
39. Meltzer HY, Bastani B, Ramirez L, Matsubara S. Clozapine: new research on efficacy and
mechanism of action. Eur Arch Psychiatry Neurol Sci 1989; 238:332-339.
40. Kapur S, Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic
action: still necessary and may even be sufficient. Biol Psychiatry 2001; 50:873-883.
41. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin
Psychiatry 1999; 60(Suppl. 10):5-14.
135